AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26600645
Drug: Aqueous extract
RxNorm normalized name: green tea aqueous extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous extract of Hibiscus sabdariffa (150 mg/kg/day)
Trial: 11468543
Drug: Lisinopril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (10 mg once daily)
Trial: 26600645
Drug: Placebo (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (150 mg/kg/day)
Trial: 16644434
Drug: Increased preload
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased preload by rapid infusion of 30 mL/kg of saline over 15 minutes
Trial: 12756423
Drug: Drug-herb interaction
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug-herb interaction pairs involving herbal products and drugs
Trial: 8701626
Drug: Danazol (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danazol (600 mg/die)
Trial: 6430811
Drug: Molsidomine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Molsidomine (2 mg 4 times daily)
Trial: 6430811
Drug: Isosorbide dinitrate
RxNorm normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isosorbide dinitrate (10 mg 4 times daily)
Trial: 30395548
Drug: Daily Right
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily Right Unilateral Ultrabrief ECT (RULUB)
Trial: 27161974
Drug: No systemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No systemic treatment (n = 288)
Trial: 21213495
Drug: Mefenamic acid,
RxNorm normalized name: Mefenamic Acid, 250 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefenamic acid, 500 mg per oral three times a day for 5 days
Trial: 11715356
Drug: Neutral endopeptidase
RxNorm normalized name: Neutral endopeptidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neutral endopeptidase inhibitors (in combination with ACE inhibitors)
Trial: 11715356
Drug: Endothelin-1 antagonists
RxNorm normalized name: nitric oxide synthase endothelial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endothelin-1 antagonists
Trial: 7626915
Drug: Inhaled bimakalim
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bimakalim (cumulative doses of 10, 25, 40, and 100 micrograms, total cumulative dose 175 micrograms)
Trial: 2510115
Drug: IgG Cutter
RxNorm normalized name: Cocoa Butter
DrugBank: Cocoa butter (DB11086)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IgG Cutter 0.6 mg per Kg BW per week
Trial: 825821
Drug: Parenteral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral supplementation with dextrose and amino acids (67 cal/dl formula feeding)
Trial: 825821
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding (100 cal/dl formula feeding)
Trial: 825821
Drug: Parenteral supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral supplementation
Trial: 29049577
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention to reduce inappropriate antibiotic prescribing
Trial: 26555159
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of danoprevir (100 mg three times daily) and mericitabine (500 mg twice daily)
Trial: 26555159
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of danoprevir (600 mg twice daily) and mericitabine (1,000 mg twice daily)
Trial: 26555159
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mericitabine and ritonavir‐boosted danoprevir
Trial: 19614805
Drug: T80 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T80 mg plus A10 mg
Trial: 19614805
Drug: A10 mg
RxNorm normalized name: Antineoplaston A10
DrugBank: Antineoplaston A10 (DB11702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A10 mg
Trial: 15173858
Drug: Epirubicin 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 90 mg m(‐2) plus Paclitaxel 200 mg m(‐2) (3‐h infusion) on day 1 every 3 weeks for eight courses (arm A)
Trial: 15173858
Drug: Epirubicin 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 120 mg m(‐2) on day 1 every 3 weeks for four courses followed by four courses of Paclitaxel 250 mg m(‐2) on day 1 every 3 weeks (arm B)
Trial: 12473876
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (participants with antihypertensive drug treatment)
Trial: 19174586
Drug: Noncontact, nonthermal,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noncontact, nonthermal, low-frequency ultrasound therapy
Trial: 16717032
Drug: Ximelagatran (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (2 x 36 mg)
Trial: 12489490
Drug: Ximelagatran (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ximelagatran (2 x 24 mg daily)
Trial: 12489490
Drug: Subcutaneous LMW
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous LMW heparin followed by warfarin
Trial: 30286851
Drug: Oxycodone (OXY)
RxNorm normalized name: oxycodone hydrochloride Oral Tablet [M-Oxy]
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oxycodone (OXY) 5 mg
Trial: 30286851
Drug: Ibuprofen (IBU)
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen (IBU) 600 mg
Trial: 30286851
Drug: Acetaminophen (ACE)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (ACE) 500 mg
Trial: 30810754
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (non-opioid medications)
Trial: 28750677
Drug: Inhaled AP301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled AP301
Trial: 26378637
Drug: Aldoxorubicin 350
RxNorm normalized name: Aldoxorubicin
DrugBank: Aldoxorubicin (DB06013)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aldoxorubicin 350 mg/m2
Trial: 26378637
Drug: Doxorubicin 75
RxNorm normalized name: DOXOrubicin 75 mg intravenous powder for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 75 mg/m2
Trial: 23514733
Drug: LY2189102 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2189102 0.6 mg
Trial: 23514733
Drug: LY2189102 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2189102 18 mg
Trial: 23514733
Drug: LY2189102 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2189102 180 mg
Trial: 14504122
Drug: 1-day quadruple
RxNorm normalized name: HUMAN PULMONARY SURFACTANT-ASSOCIATED PROTEIN D (PSPD, SURFACTANT PROTEIN D, SP-D, COLLECTIN-7, SURFACTANT PROTEIN D), NON-COVALENT QUADRUPLE TRIMER, PRODUCED IN HUMAN MYELOGENOUS LEUKEMIA K562 CELLS, GLYCOFORME ALFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-day quadruple therapy (4-drug regimen)
Trial: 14504122
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy (3-drug regimen)
Trial: 10802469
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine infusion at 2 mL per hour
Trial: 10802469
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion at 2 mL per hour
Trial: 8874303
Drug: Dexamethasone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (0.5 mg/kg, maximum dose 10 mg)
Trial: 6298318
Drug: Topical acyclovir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical acyclovir applied six times daily for five days
Trial: 26242184
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonist (GLP-1RA) therapy
Trial: 17074146
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (aspirin, clopidogrel, cilostazol)
Trial: 29273207
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (aspirin, clopidogrel, placebo)
Trial: 28329061
Drug: Peginterferon add-on
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon add-on therapy (n = 39)
Trial: 28329061
Drug: NA monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA monotherapy (n = 38)
Trial: 28329061
Drug: Peginterferon add-on
RxNorm normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Peginterferon add-on therapy (among 58 interferon-naive patients)
Trial: 28329061
Drug: NA monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA monotherapy (among 58 interferon-naive patients)
Trial: 28329061
Drug: Responders at
RxNorm normalized name: rose bengal AT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Responders at week 48 who discontinued NA therapy at week 72 (n = 8)
Trial: 28329061
Drug: Add-on therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on therapy group (n = 6)
Trial: 28329061
Drug: Monotherapy group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy group (n = 2)
Trial: 21215350
Drug: CB‐CIK +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CB‐CIK + Chemotherapy
Trial: 18792997
Drug: Ultrasound-guided extracorporeal
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided extracorporeal shock wave therapy (ESWT)
Trial: 18792997
Drug: Subtherapeutic dose
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subtherapeutic dose treatment
Trial: 16421419
Drug: FOLFOX4 administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX4 administered every 2 weeks until progression (arm A)
Trial: 8324432
Drug: Multivitamin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multivitamin supplementation (0.8 mg of folic acid)
Trial: 8324432
Drug: Trace elements
RxNorm normalized name: trace elements
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trace elements supplement
Trial: 18824608
Drug: BILR 355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILR 355 alone (12.5 mg to 100 mg)
Trial: 18824608
Drug: BILR 355
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BILR 355 with ritonavir (RTV) (5 mg to 87.5 mg)
Trial: 19116439
Drug: Medicine-ball chest
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medicine-ball chest passes
Trial: 1517839
Drug: 131I‐chimeric B72.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 131I‐chimeric B72.3 (IgG‐4) at total doses of 28 or 36 mCi/m2 in two or three weekly fractions
Trial: 1517839
Drug: 131I‐chimeric B72.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 131I‐chimeric B72.3 (IgG‐4) at total doses of 36 mCi/m2
Trial: 1517839
Drug: Second course
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second course of therapy with 131I‐chimeric B72.3 (IgG‐4)
Trial: 1517839
Drug: Dose fractionation
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose fractionation of 131I‐chimeric B72.3 (IgG‐4)
Trial: 6468471
Drug: SUR 2647
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SUR 2647 combination (2 sachets b.i.d. on the day of operation, 1 sachet b.i.d. for the following two days)
Trial: 6468471
Drug: Paracetamol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (2 tablets q.i.d. on the day of operation, 1 tablet q.i.d. for the following two days)
Trial: 30417227
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 0.015 mg/ml epinephrine (Group A)
Trial: 30417227
Drug: 2% lidocaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% lidocaine with 0.015 mg/ml epinephrine (Group B)
Trial: 30417227
Drug: 4% articaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% articaine with 0.012 mg/ml epinephrine (Group C)
Trial: 25676674
Drug: Lansoprazole OD
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lansoprazole OD 30 mg from a nasogastric tube for 14 days
Trial: 20040336
Drug: Bezafibrate (BF)
RxNorm normalized name: bezafibrate
DrugBank: Bezafibrate (DB01393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bezafibrate (BF) administration
Trial: 8826310
Drug: Automated medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated medication distribution systems
Trial: 3931802
Drug: Yoga exercises
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Yoga exercises including breathing exercises, suryanamaskar, yogasana, pranayama, dhyana, and a devotional session practiced for 65 minutes daily.
Trial: 3931802
Drug: Usual drugs
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual drugs (control group).
Trial: 29300977
Drug: Salk polio
RxNorm normalized name: poliovirus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salk polio vaccine
Trial: 27609809
Drug: AS03-adjuvanted vaccines
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS03-adjuvanted vaccines (low or medium dose of hemagglutinin with AS03A or AS03B)
Trial: 27609809
Drug: Adjuvanted vaccines
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvanted vaccines
Trial: 21291034
Drug: 6 mg/day
RxNorm normalized name: EMSAM 6 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/day 17beta‐estradiol (E2) orally with progesterone vaginal gel
Trial: 21291034
Drug: Progesterone vaginal
RxNorm normalized name: progesterone Vaginal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Progesterone vaginal gel without 6 mg/day 17beta‐estradiol (E2)
Trial: 18344178
Drug: Antioxidant tablets
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidant tablets
Trial: 12053635
Drug: Sertraline (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (50 to 100 mg/d)
Trial: 12053635
Drug: St John's
RxNorm normalized name: St john's wort
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: St John's wort (900 to 1800 mg/d)
Trial: 6354607
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg proglumetacin twice daily
Trial: 25416642
Drug: 24 IU
RxNorm normalized name: Nasopro 24
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 24 IU intranasal oxytocin (OT)
Trial: 25416642
Drug: 20 IU
RxNorm normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU intranasal vasopressin (AVP)
Trial: 8656259
Drug: Etoposide 2
RxNorm normalized name: etoposide 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide 2 micrograms/mL
Trial: 8656259
Drug: Etoposide 3
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Etoposide 3 micrograms/mL
Trial: 30620868
Drug: 0.96% zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.96% zinc (zinc oxide, zinc citrate), 1.5% L‐arginine and 1450 ppm fluoride as sodium fluoride in a silica base, Test 1
Trial: 30620868
Drug: 0.96% zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.96% zinc (zinc oxide, zinc citrate), 1.5% L‐arginine and 1000 ppm fluoride as sodium fluoride in a silica base, Test 2
Trial: 27264058
Drug: 800 IU
RxNorm normalized name: Vitamin E 800 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 IU cholecalciferol daily
Trial: 29423540
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (ACEI)
Trial: 1725911
Drug: High-dose verapamil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose verapamil treatment (Isoptin RR 240 mg twice daily)
Trial: 1725911
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of nifedipine four times daily
Trial: 1725911
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg of diltiazem three times daily
Trial: 20693587
Drug: Caffeine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (5 mg per kg of body weight)
Trial: 14556918
Drug: Various chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various chemotherapy regimens for advanced NSCLC
Trial: 14556918
Drug: Platinum and/or
RxNorm normalized name: Platinum and/or platinum compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum and/or taxane and combination regimens
Trial: 1726209
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil suspension (3 and 6 mg/kg)
Trial: 7036336
Drug: Pirenzepine (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (75 mg daily)
Trial: 31876200
Drug: MTX +
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX + CsA (7.5 mg MTX and 2.5 mg/kg CsA)
Trial: 31876200
Drug: MTX +
RxNorm normalized name: MTX
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MTX + Placebo (7.5 mg MTX and placebo)
Trial: 25782170
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg ambroxol (AXS)
Trial: 25782170
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg ambroxol (AXS)
Trial: 25782170
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg ambroxol (AXS)
Trial: 21324570
Drug: Quercetin 4x500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quercetin 4x500 mg orally within 24 hours
Trial: 26687616
Drug: 5-aminolevulinic acid
RxNorm normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5-aminolevulinic acid photodynamic therapy (ALA-PDT)
Trial: 19470041
Drug: 5% imiquimod
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% imiquimod cream (IMIQ)
Trial: 17481859
Drug: Rapid intravenous
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid intravenous administration of meta-chlorophenylpiperazine (m-CPP) at a dosage of 0.1 mg/kg
Trial: 15047131
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg rhIGF‐I/IGFBP‐3 for one‐week intervals
Trial: 9551246
Drug: Ceftriaxone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (100 mg/kg on the first day followed by 75 mg/kg/day)
Trial: 9551246
Drug: Cefotaxime (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefotaxime (200 mg/kg/day in four divided doses)
Trial: 233545
Drug: Oral metaproterenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral metaproterenol administered daily for 3 months
Trial: 31636172
Drug: Metformin or
RxNorm normalized name: metformin Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin or placebo
Trial: 21991942
Drug: Pre-bronchodilator lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-bronchodilator lung function
Trial: 21991942
Drug: Post-bronchodilator lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-bronchodilator lung function
Trial: 21991942
Drug: Pre-bronchodilator lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-bronchodilator lung function (Stage 3 or 4 disease)
Trial: 21991942
Drug: Post-bronchodilator lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-bronchodilator lung function (Stage 3 or 4 disease)
Trial: 21991942
Drug: Pre-bronchodilator lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-bronchodilator lung function (Year 5 sample)
Trial: 21991942
Drug: Post-bronchodilator lung
RxNorm normalized name: beef lung preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-bronchodilator lung function (Year 5 sample)
Trial: 16867142
Drug: Treatment effects
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment effects analysis using fecal terminal restriction fragment length polymorphism data sets
Trial: 6468034
Drug: 3 X
RxNorm normalized name: Xenon (133 xe)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 X 1500 mg Cefuroxim (Zinazef) for three days, starting 1 h prior to the operation
Trial: 24003241
Drug: Guaifenesin (GGE)
RxNorm normalized name: Guaifenesin
DrugBank: Guaifenesin (DB00874)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Guaifenesin (GGE) 600 mg extended-release tablets, taken twice daily for 8 days
Trial: 19930235
Drug: Oral Naltrexone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Naltrexone + Brief Behavioral Compliance Enhancement Therapy (BBCET) + treatment as usual (TAU)